M4di variant
By optimizing the hM4Di receptor through molecular biology and protein engineering, enhancing the sensitivity of exogenous ligands and prolonging the desensitization time, the problem of the lack of sustained therapeutic effect of hM4Di receptor in pain treatment was solved, achieving more effective long-term therapeutic effects and reducing side effects.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- CHINESE INST FOR BRAIN RES BEIJING
- Filing Date
- 2025-12-25
- Publication Date
- 2026-07-02
AI Technical Summary
The existing hM4Di receptor is limited in its ability to treat pain due to ligand sensitivity, response intensity, and desensitization time, resulting in inconsistent therapeutic effects. High doses of CNO may cause nonspecific effects, which limits the practicality and effectiveness of long-term treatment.
By optimizing the hM4Di receptor through molecular biology and protein engineering, we can enhance its sensitivity to exogenous ligands and prolong the desensitization time. By combining it with excitatory neuron-specific promoters, we can improve its targeting and inhibitory efficacy and reduce the risk of side effects.
It enables sustained therapeutic effects with lower doses of exogenous ligands, enhances targeting of specific neuronal subsets, reduces non-specific effects, and improves the long-term efficacy of chemogenetic therapy.
Smart Images
Figure 00000049_0000 
Figure 00000050_0000 
Figure 00000051_0000